Spyre Therapeutics, Inc. (SYRE)

23,09 -1,14 (-4,70%) Alla chiusura: 04:00PM EDT

Spyre Therapeutics, Inc.

221 Crescent Street
Building 23 Suite 105
Waltham, MA 02453
United States
617 651 5940
https://www.spyre.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 30

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Cameron Turtle DPHIL, Ph.D.	CEO & Director	674,17k	N/D	1990
Mr. Scott L. Burrows	Chief Financial Officer	331,81k	N/D	1977
Ms. Heidy Abreu King-Jones J.D., L.L.M.	Chief Legal Officer & Corporate Secretary	568,87k	N/D	1983
Dr. Janet Gunzner-Toste M.B.A., Ph.D.	Senior Vice President of Operations	N/D	N/D	N/D
Mr. Brian Connolly	Chief Technical Officer	N/D	N/D	N/D
Mr. Eric McIntyre	Vice President of Finance & Investor Relations	N/D	N/D	N/D
Mr. James Myers	Vice President of Quality & Compliance	N/D	N/D	N/D
Dr. Kelly Boothe Ph.D.	Senior Director of Corporate Communications & Investor Relations	N/D	N/D	N/D
Dr. Justin LaFountaine Ph.D.	Senior Vice President of Corporate Development	N/D	N/D	N/D
Ms. Melissa Cooper	Senior Vice President of People	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Spyre Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.